Alcresta Therapeutics
Medical Devices, 130 Turner St, Newton, Massachusetts, 02453, United States, 11-50 Employees
Who is ALCRESTA THERAPEUTICS
Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and...
Read More
-
Headquarters: 130 Turner St, Newton, Massachusetts, 02453, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
-
CEO:
Anne Smith
Email
Phone
Industry: Medical Devices
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from ALCRESTA THERAPEUTICS
Alcresta Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Alcresta Therapeutics
Answer: Alcresta Therapeutics's headquarters are located at 130 Turner St, Newton, Massachusetts, 02453, United States
Answer: Alcresta Therapeutics's official website is https://alcresta.com
Answer: Alcresta Therapeutics's revenue is $25 Million to $50 Million
Answer: Alcresta Therapeutics's SIC: 2834
Answer: Alcresta Therapeutics's NAICS: 561110
Answer: Alcresta Therapeutics has 11-50 employees
Answer: Alcresta Therapeutics is in Medical Devices
Answer: Alcresta Therapeutics contact info: Phone number: Website: https://alcresta.com
Answer: Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The companys lead product, RELiZORB, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The companys platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Alcresta Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month